Company: SNWV
Filing Date: 2025-07-10
Form Type: DEF 14A
Source: 0001140361-25-025486
Chunk: 9

Company: SANUWAVE Health, Inc.
Filing Date: 2025-07-10
Form: DEF 14A
Chunk 9
---
 (LD) |     |  49 |     | April 2022     |     | Yes         |     | C, F |     | —  |     | M   |     | M  |
| James Tyler     |     |  68 |     | April 2021     |     | Yes         |     | M    |     | M  |     | C   |     | M  |
| Gregory Bazar   |     |  50 |     | May 2025       |     | Yes         |     |      |     | M  |     |     |     |    |

| C:  |     | Committee Chair                |     | M:  |     | Member                    |     | F:   |     | Financial Expert         |
| AC: |     | Audit Committee                |     | CC: |     | Compensation Committee    |     | NCG: |     | Nominating and Corporate |
| SF: |     | Strategy and Finance Committee |     | LD: |     | Independent Lead Director |     |      |     | Governance Committee     |

A brief biography of each nominee is set forth below, which includes information, as of the Record Date, regarding specific and particular experience, qualifications, attributes, or skills of each nominee that led the Nominating and Corporate Governance Committee and the Board to believe that the director should serve on the Board. Director Nominees Morgan Frank joined the Board as Chairman in August 2022 and was appointed Chief Executive Officer in May 2023. Mr. Frank is a founder and principal at Manchester Explorer Fund (19 years) and at Manchester Explorer Ltd (Cayman), two life science focused public equity hedge funds specializing in hands-on microcap growth and development companies. He has over 30 years of experience in investing, capital markets, corporate strategy, corporate finance, corporate restarts, and intellectual property. Mr. Frank was formerly a principal at First Principles Group, a firm focused on corporate restarts, and a portfolio manager for technology and venture capital at Hollis Capital, a San Francisco hedge fund. He also sits on the board of Modular Medical, Inc. (MODD), a development stage company focused on next generation insulin delivery. Mr. Frank has degrees in economics and political science from Brown University. The Board believes that Mr. Frank’s extensive experience in life sciences investing, corporate restructuring, and public company leadership qualify him to serve on the Board. Jeffrey Blizard joined the Board as a Director